These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34895161)

  • 21. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269.
    Stella M; Giuliani M; Biolchi A; Tomei S; De Paola R; Bai X; Borrow R; Lucidarme J; La Gaetana R; Toneatto D; Pizza M; Serino L; Mori E; Giuliani MM
    Hum Vaccin Immunother; 2020 Apr; 16(4):945-948. PubMed ID: 31770063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents.
    McMillan M; Wang B; Koehler AP; Sullivan TR; Marshall HS
    Clin Infect Dis; 2021 Jul; 73(1):e233-e237. PubMed ID: 33587122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of expanded
    Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
    Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.
    Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R
    J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
    Ohm M; Hahné SJM; van der Ende A; Sanders EAM; Berbers GAM; Ruijs WLM; van Sorge NM; de Melker HE; Knol MJ
    Clin Infect Dis; 2022 Jul; 74(12):2173-2180. PubMed ID: 34525199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
    Lucidarme J; Bai X; Lekshmi A; Clark SA; Willerton L; Ribeiro S; Campbell H; Serino L; De Paola R; Holland A; Louth J; Ramsay ME; Ladhani SN; Borrow R
    J Infect; 2022 Feb; 84(2):136-144. PubMed ID: 34838814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines.
    Argante L; Tizzoni M; Medini D
    BMC Med; 2016 Jun; 14():98. PubMed ID: 27363534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.
    Cinconze E; Rosillon D; Rappuoli R; Vadivelu K; Bekkat-Berkani R; Abbing-Karahagopian V
    Vaccine; 2023 Jul; 41(30):4347-4358. PubMed ID: 37321895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
    Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ
    CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.